246 related articles for article (PubMed ID: 34775469)
1. Emerging role of G9a in cancer stemness and promises as a therapeutic target.
Haebe JR; Bergin CJ; Sandouka T; Benoit YD
Oncogenesis; 2021 Nov; 10(11):76. PubMed ID: 34775469
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel small molecule inhibitors of lysine methyltransferase G9a and their mechanism in leukemia cell lines.
Kondengaden SM; Luo LF; Huang K; Zhu M; Zang L; Bataba E; Wang R; Luo C; Wang B; Li KK; Wang PG
Eur J Med Chem; 2016 Oct; 122():382-393. PubMed ID: 27393948
[TBL] [Abstract][Full Text] [Related]
3. The dopamine transporter antagonist vanoxerine inhibits G9a and suppresses cancer stem cell functions in colon tumors.
Bergin CJ; Zouggar A; Mendes da Silva A; Fenouil T; Haebe JR; Masibag AN; Agrawal G; Shah MS; Sandouka T; Tiberi M; Auer RC; Ardolino M; Benoit YD
Nat Cancer; 2024 Mar; 5(3):463-480. PubMed ID: 38351181
[TBL] [Abstract][Full Text] [Related]
4. G9a controls pluripotent-like identity and tumor-initiating function in human colorectal cancer.
Bergin CJ; Zouggar A; Haebe JR; Masibag AN; Desrochers FM; Reilley SY; Agrawal G; Benoit YD
Oncogene; 2021 Feb; 40(6):1191-1202. PubMed ID: 33323965
[TBL] [Abstract][Full Text] [Related]
5. G9a regulates tumorigenicity and stemness through genome-wide DNA methylation reprogramming in non-small cell lung cancer.
Pangeni RP; Yang L; Zhang K; Wang J; Li W; Guo C; Yun X; Sun T; Wang J; Raz DJ
Clin Epigenetics; 2020 Jun; 12(1):88. PubMed ID: 32552834
[TBL] [Abstract][Full Text] [Related]
6. Histone methyltransferase G9a and H3K9 dimethylation inhibit the self-renewal of glioma cancer stem cells.
Tao H; Li H; Su Y; Feng D; Wang X; Zhang C; Ma H; Hu Q
Mol Cell Biochem; 2014 Sep; 394(1-2):23-30. PubMed ID: 24833465
[TBL] [Abstract][Full Text] [Related]
7. Targeting histone methyltransferase G9a inhibits growth and Wnt signaling pathway by epigenetically regulating HP1α and APC2 gene expression in non-small cell lung cancer.
Zhang K; Wang J; Yang L; Yuan YC; Tong TR; Wu J; Yun X; Bonner M; Pangeni R; Liu Z; Yuchi T; Kim JY; Raz DJ
Mol Cancer; 2018 Oct; 17(1):153. PubMed ID: 30348169
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic Regulation of the PTEN-AKT-RAC1 Axis by G9a Is Critical for Tumor Growth in Alveolar Rhabdomyosarcoma.
Bhat AV; Palanichamy Kala M; Rao VK; Pignata L; Lim HJ; Suriyamurthy S; Chang KT; Lee VK; Guccione E; Taneja R
Cancer Res; 2019 May; 79(9):2232-2243. PubMed ID: 30833420
[TBL] [Abstract][Full Text] [Related]
9. The methyltransferase G9a regulates HoxA9-dependent transcription in AML.
Lehnertz B; Pabst C; Su L; Miller M; Liu F; Yi L; Zhang R; Krosl J; Yung E; Kirschner J; Rosten P; Underhill TM; Jin J; Hébert J; Sauvageau G; Humphries RK; Rossi FM
Genes Dev; 2014 Feb; 28(4):317-27. PubMed ID: 24532712
[TBL] [Abstract][Full Text] [Related]
10. Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma.
Colyn L; Bárcena-Varela M; Álvarez-Sola G; Latasa MU; Uriarte I; Santamaría E; Herranz JM; Santos-Laso A; Arechederra M; Ruiz de Gauna M; Aspichueta P; Canale M; Casadei-Gardini A; Francesconi M; Carotti S; Morini S; Nelson LJ; Iraburu MJ; Chen C; Sangro B; Marin JJG; Martinez-Chantar ML; Banales JM; Arnes-Benito R; Huch M; Patino JM; Dar AA; Nosrati M; Oyarzábal J; Prósper F; Urman J; Cubero FJ; Trautwein C; Berasain C; Fernandez-Barrena MG; Avila MA
Hepatology; 2021 Jun; 73(6):2380-2396. PubMed ID: 33222246
[TBL] [Abstract][Full Text] [Related]
11. Targeting EHMT2/ G9a for cancer therapy: Progress and perspective.
Jan S; Dar MI; Wani R; Sandey J; Mushtaq I; Lateef S; Syed SH
Eur J Pharmacol; 2021 Feb; 893():173827. PubMed ID: 33347828
[TBL] [Abstract][Full Text] [Related]
12. The Histone Methyltransferase Inhibitor A-366 Uncovers a Role for G9a/GLP in the Epigenetics of Leukemia.
Pappano WN; Guo J; He Y; Ferguson D; Jagadeeswaran S; Osterling DJ; Gao W; Spence JK; Pliushchev M; Sweis RF; Buchanan FG; Michaelides MR; Shoemaker AR; Tse C; Chiang GG
PLoS One; 2015; 10(7):e0131716. PubMed ID: 26147105
[TBL] [Abstract][Full Text] [Related]
13. The histone methyltransferase G9a: a new therapeutic target in biliary tract cancer.
Mayr C; Helm K; Jakab M; Ritter M; Shrestha R; Makaju R; Wagner A; Pichler M; Beyreis M; Staettner S; Jaeger T; Klieser E; Kiesslich T; Neureiter D
Hum Pathol; 2018 Feb; 72():117-126. PubMed ID: 29133140
[TBL] [Abstract][Full Text] [Related]
14. EHMT2/G9a as an Epigenetic Target in Pediatric and Adult Brain Tumors.
Souza BK; Freire NH; Jaeger M; de Farias CB; Brunetto AL; Brunetto AT; Roesler R
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681949
[TBL] [Abstract][Full Text] [Related]
15. Structure, Activity, and Function of the Protein Lysine Methyltransferase G9a.
Poulard C; Noureddine LM; Pruvost L; Le Romancer M
Life (Basel); 2021 Oct; 11(10):. PubMed ID: 34685453
[TBL] [Abstract][Full Text] [Related]
16. Coordinated recruitment of histone methyltransferase G9a and other chromatin-modifying enzymes in SHP-mediated regulation of hepatic bile acid metabolism.
Fang S; Miao J; Xiang L; Ponugoti B; Treuter E; Kemper JK
Mol Cell Biol; 2007 Feb; 27(4):1407-24. PubMed ID: 17145766
[TBL] [Abstract][Full Text] [Related]
17. Deletion of Histone Methyltransferase G9a Suppresses Mutant Kras-driven Pancreatic Carcinogenesis.
Kato H; Tateishi K; Fujiwara H; Ijichi H; Yamamoto K; Nakatsuka T; Kakiuchi M; Sano M; Kudo Y; Hayakawa Y; Nakagawa H; Tanaka Y; Otsuka M; Hirata Y; Tachibana M; Shinkai Y; Koike K
Cancer Genomics Proteomics; 2020; 17(6):695-705. PubMed ID: 33099471
[TBL] [Abstract][Full Text] [Related]
18. The H3K9 Methyltransferase G9a Represses E-cadherin and is Associated with Myometrial Invasion in Endometrial Cancer.
Hsiao SM; Chen MW; Chen CA; Chien MH; Hua KT; Hsiao M; Kuo ML; Wei LH
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1556-65. PubMed ID: 25613390
[TBL] [Abstract][Full Text] [Related]
19. G9a - An Appealing Antineoplastic Target.
Chen WL; Sun HP; Li DD; Wang ZH; You QD; Guo XK
Curr Cancer Drug Targets; 2017; 17(6):555-568. PubMed ID: 27174055
[TBL] [Abstract][Full Text] [Related]
20. G9a governs colon cancer stem cell phenotype and chemoradioresistance through PP2A-RPA axis-mediated DNA damage response.
Luo CW; Wang JY; Hung WC; Peng G; Tsai YL; Chang TM; Chai CY; Lin CH; Pan MR
Radiother Oncol; 2017 Sep; 124(3):395-402. PubMed ID: 28351524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
